EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access

Nirsevimab effectiveness against hospital admission for respiratory syncytial virus bronchiolitis in infants

R Rodríguez-Fernández, F González-Martínez, I Ojeda Velázquez, M Rodríguez Díaz, M V Capozzi Bucciol, M I González-Sánchez, J Pérez-Moreno, B Toledo Del Castillo

Revista Española de Quimioterapia · 2024

DOI: 10.37201/req/026.2024 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Revista Española de Quimioterapia, 2024. Verfasst von R Rodríguez-Fernández und 7 weiteren Autor:innen. Beteiligte Einrichtung: Rosa Rodriguez-Fernández. Sección de Pediatría Interna Hospitalaria. Servicio de Pediatría. Hospital Gregorio Marañón. Calle O'Donnell 50, 28007, Mad…. Hauptthemen laut MEDLINE: Respiratory Syncytial Virus Infections, Antibodies, Monoclonal, Humanized, Hospitalization, Antiviral Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction. Respiratory syncytial virus (RSV) bronchiolitis is the leading cause of hospitalization in infants. This season, a long half-life monoclonal antibody (Nirsevimab) is available to prevent this disease for all infants born from 1 April-30 September to 2023 and all those born during RSV season (October2023- March 2024). The aim of this study was to evaluate the impact of the implementation of this antibody on RSV admissions in a tertiary hospital. Material and methods. Observational, retrospective and analytical study. All patients

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Respiratory Syncytial Virus InfectionsAntibodies, Monoclonal, HumanizedHospitalizationAntiviral AgentsHumansInfantRetrospective StudiesMaleFemaleBronchiolitisBronchiolitis, ViralInfant, NewbornTreatment Outcome

Stichwörter der Autor:innen

BronchiolitisRSVmonoclonal antibodiesnirsevimabprevention

Substanzen

Antibodies, Monoclonal, HumanizedAntiviral Agentsmotavizumab

Autor:innen und Institutionen

  • Rosa Rodriguez-Fernández. Sección de Pediatría Interna Hospitalaria. Servicio de Pediatría. Hospital Gregorio Marañón. Calle O'Donnell 50, 28007, Madrid, Spain. rrfernandez@salud.madrid.org.

Zitieren

APA

Rodríguez-Fernández, R., González-Martínez, F., Ojeda Velázquez, I., Rodríguez Díaz, M., Capozzi Bucciol, M. V., González-Sánchez, M. I., Pérez-Moreno, J., & Toledo Del Castillo, B. (2024). Nirsevimab effectiveness against hospital admission for respiratory syncytial virus bronchiolitis in infants. Revista Española de Quimioterapia. https://doi.org/10.37201/req/026.2024

Vancouver

Rodríguez-Fernández R, González-Martínez F, Ojeda Velázquez I, Rodríguez Díaz M, Capozzi Bucciol MV, González-Sánchez MI, et al. Nirsevimab effectiveness against hospital admission for respiratory syncytial virus bronchiolitis in infants. Revista Española de Quimioterapia. 2024. doi:10.37201/req/026.2024

BibTeX
@article{RodrguezFernndez2024,
  author = {Rodríguez-Fernández, R and González-Martínez, F and Ojeda Velázquez, I and Rodríguez Díaz, M and Capozzi Bucciol, M V and González-Sánchez, M I and Pérez-Moreno, J and Toledo Del Castillo, B},
  title = {Nirsevimab effectiveness against hospital admission for respiratory syncytial virus bronchiolitis in infants},
  journal = {Revista Española de Quimioterapia},
  year = {2024},
  doi = {10.37201/req/026.2024}
}
Kostenlos starten →